Mepolizumab Dosage

Usual Adult Dose for Asthma - Maintenance

100 mg subcutaneously every 4 weeks

Comment:
-This drug should be administered in the upper arm, thigh, or abdomen.
-The need for continued therapy with this drug should be assessed at least annually.

Use: Add-on maintenance treatment for severe asthma with an eosinophilic phenotype

Usual Pediatric Dose for Asthma - Maintenance

12 years or older:
100 mg subcutaneously every 4 weeks

Comment:
-This drug should be administered in the upper arm, thigh, or abdomen.

Use: Add-on maintenance therapy for severe asthma with an eosinophilic phenotype

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug should be reconstituted and administered by a health care provider.
-Discard if cloudy, milky, or particulate matter remains in solution after reconstitution.
-Subcutaneous administration in upper arm, thigh, or abdomen is preferred.

Storage requirements:
-Lyophilized powder: Protect from light; do not freeze.
-Reconstituted solution: Do not freeze; discard if not used within 6 to 8 hours of reconstitution.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

General:
-This drug should not be used to treat other eosinophilic conditions, acute asthma, bronchospasm, or status asthmaticus.
-Avoid decreasing or discontinuing corticosteroids during initiation of this drug.
-This drug may interfere with helminth infections.
-Hypersensitivity reactions may occur up to days after administration.
-This drug should be prescribed by healthcare professionals experienced in the diagnosis and treatment of severe asthma.

Monitoring:
-Signs and symptoms of uncontrolled or worsening asthma
-Signs and symptoms of an allergic reaction (e.g., facial swelling, rash, hypotension, hives)

Patient advice:
-Warn patients to avoid interruptions or abrupt discontinuation of corticosteroids.
-Instruct patients to notify their healthcare provider upon signs and symptoms of worsening asthma or allergic reaction.
-Patients should be advised to speak to their healthcare provider if pregnant, intend to become pregnant, or are breastfeeding.